Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): A pharmacokinetic evaluation in HIV-positive patients

Journal of Clinical Pharmacology

Volumn 39, Issue 10, 1999, Pages 1085-1093

  Hayashi, S ^a   Jayesekera, D ^a   Jayewardene, A ^a   Shah, A ^a   Thevanayagam, L ^a   Aweeka, F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; TALVIRALINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE;

EID: 0033328289     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922011746     Document Type: Article

References (22)

1. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors
2. HIV-1-specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase
3. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients
4. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus
5. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection
6. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy
7. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients (abstract 374)
8. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals (abstract 568)
9. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers
10. Preclinical evaluation of H.E.Y. 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication
11. HBY097, in vitro antiviral profile against HIV-1 in acute and persistent infection systems; combined drug interaction with different inhibitor of HIV-1-or other viruses
12. Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography
13. Validation of a liquid chromatographic/mass spectrometric/mass spectrometricanalysis for the determination of indinavir in human plasma
14. Quantitative analysis of HEY 097 and its metabolites in human serum and urine by HPLC
15. Use of in vitro and in vive data to estimate the likelihood of metabolic pharmacokinetic interactions
16. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine
17. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy
18. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers
19. Delavirdine and nelfinavir: A pharmacokinetic drug-drug interaction study in healthy adult volunteers
20. Ritonavir pharmacokinetics during combination therapy with delavirdine
21. Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers